The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury

被引:75
作者
Hoane, Michael R. [1 ]
Kaplan, Shelby A. [1 ]
Ellis, Amy L. [1 ]
机构
[1] So Illinois Univ, Restorat Neurosci Lab, Brain & Cognit Sci Program, Dept Psychol,Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA
关键词
TBI; neuronal death; neuroprotection; treatment; vitamin B3; nicotinamide; rat;
D O I
10.1016/j.brainres.2006.10.019
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Nicotinamide has been shown to protect against many of the pathophysiological factors associated with both ischemic and traumatic brain injuries. The present study evaluated the neuroprotective effect of nicotinamide on the breakdown of the blood-brain barrier (BBB) and apoptosis expression following traumatic brain injury (TBI). Animals were prepared with a unilateral cortical contusion injury (CCI). Fifteen minutes following injury the animals received either nicotinamide (500 mg/kg, ip) or 0.9% saline. The animals were perfused at 5, 24, and 72 h post-injury. BBB integrity was assessed by endogenous rat IgG immunoreactivity. Recent studies have shown that IgG immunoreactivity is a reliable measure of BBB integrity. The results indicated that IgG immunoreactivity was greatest at 5 h and declined at 24 h after injury. Nicotinamide significantly reduced IgG expression at every time point following injury. Apoptosis was examined using the TUNEL method. The results indicated that TUNEL immunoreactivity peaked at 24 h. TUNEL+ cells were classified morphologically as nonapoptotic (Type I) or apoptotic (Type II) to verify that the neuroprotective effects of nicotinamide occur by inhibiting apoptosis or necrosis. Administration of nicotinamide significantly reduced the expression of all TUNEL+ cells in the tissue surrounding the lesion cavity. Specifically there was a significant reduction in the number of Type I, Type II and Total TUNEL+ cells in the nicotinamide-treated animals. in addition, nicotinamide reduced lesion cavity expansion 72 h following CCI. These findings suggest that nicotinamide reduces BBB breach and neuronal cell loss acutely following injury and that these reductions may account for the beneficial behavioral effects seen in previous studies. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:185 / 193
页数:9
相关论文
共 32 条
[21]   Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain [J].
Maiese, K ;
Chong, ZZ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (05) :228-232
[22]  
Maynard KI, 2001, ANN NY ACAD SCI, V939, P416
[23]   Delayed treatment with nicotinamide (vitamin B3) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats [J].
Mokudai, T ;
Ayoub, IA ;
Sakakibara, Y ;
Lee, EJ ;
Ogilvy, CS ;
Maynard, KI .
STROKE, 2000, 31 (07) :1679-1684
[24]   Microvascular basal lamina antigen loss after traumatic brain injury in the rat [J].
Muellner, A ;
Benz, M ;
Kloss, CUA ;
Mautes, A ;
Burggraf, D ;
Hamann, GF .
JOURNAL OF NEUROTRAUMA, 2003, 20 (08) :745-754
[25]   Clinical trials in head injury [J].
Narayan, RK ;
Michel, ME .
JOURNAL OF NEUROTRAUMA, 2002, 19 (05) :503-557
[26]   Apoptosis after traumatic brain injury [J].
Raghupathi, R ;
Graham, DI ;
McIntosh, TK .
JOURNAL OF NEUROTRAUMA, 2000, 17 (10) :927-938
[27]   The simple model versus the super model: Translating experimental traumatic brain injury research to the bedside [J].
Statler, KD ;
Jenkins, LW ;
Dixon, CE ;
Clark, RSB ;
Marion, DW ;
Kochanek, PM .
JOURNAL OF NEUROTRAUMA, 2001, 18 (11) :1195-1206
[28]   FAS-INDUCED AND TUMOR NECROSIS FACTOR-INDUCED APOPTOSIS IS INHIBITED BY THE POXVIRUS CRMA GENE-PRODUCT [J].
TEWARI, M ;
DIXIT, VM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (07) :3255-3260
[29]   The therapeutic potential of poly(ADP-ribose) polymerase inhibitors [J].
Virág, L ;
Szabó, C .
PHARMACOLOGICAL REVIEWS, 2002, 54 (03) :375-429
[30]   Medicinal Chemistry of Nicotinamide in the Treatment of Ischemia and Reperfusion [J].
Yang, J. ;
Klaidman, L. K. ;
Adams, J. D. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (02) :125-134